Last updated on August 2018

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU

Brief description of study

The purpose of the study is to demonstrate the effect of Certolizumab Pegol (CZP) treatment on the reduction of Anterior Uveitis (AU) flares in subjects with active axial Spondyloarthritis (axSpA) and a documented history of AU

Clinical Study Identifier: NCT03020992

Contact Investigators or Research Sites near you

Start Over

As0007 101
Brno, Czechia

As0007 103
Brno, Czechia

As0007 107
Brno, Czechia

As0007 108
Ostrava, Czechia

As0007 109
Pardubice, Czechia

As0007 102
Praha, Czechia

As0007 105
Praha, Czechia

As0007 301
Freiburg, Germany

As0007 303
Muenster, Germany

As0007 302
Munich, Germany

As0007 401
Amsterdam, Netherlands

As0007 506
Bialystok, Poland

As0007 510
Lublin, Poland

As0007 509
Poznan, Poland

As0007 511
Poznan, Poland

As0007 502
Torun, Poland

As0007 501
Warszawa, Poland

As0007 505
Warszawa, Poland

As0007 504
Wroclaw, Poland

As0007 507
Wroclaw, Poland

As0007 508
Wroclaw, Poland

As0007 604
Barcelona, Spain

As0007 601
Córdoba, Spain

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.